AbCellera Biologics Inc Forecast, price target & analysts
Why the stock moved Beta
AbCellera Biologics Inc Target price 2025 - Analyst rating & recommendation
AbCellera Biologics Inc Classifications & Recommendation:
AbCellera Biologics Inc Price Target
| Target Price | $9.18 |
| Price | $3.61 |
| Potential |
154.29%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target AbCellera Biologics Inc 2026 .
The average AbCellera Biologics Inc target price is $9.18.
This is
154.29%
register free of charge
$17.85
394.46%
register free of charge
$5.05
39.89%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend AbCellera Biologics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AbCellera Biologics Inc stock has an average upside potential 2026 of
154.29%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 28.83 | 33.73 |
| 24.19% | 17.00% | |
| EBITDA Margin | -776.69% | -716.45% |
| 38.80% | 7.76% | |
| Net Margin | -564.90% | -551.54% |
| 46.74% | 2.36% |
11 Analysts have issued a sales forecast AbCellera Biologics Inc 2025 . The average AbCellera Biologics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an AbCellera Biologics Inc EBITDA forecast 2025. The average AbCellera Biologics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 AbCellera Biologics Inc Analysts have issued a net profit forecast 2025. The average AbCellera Biologics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.55 | -0.62 |
| 7.84% | 12.73% | |
| P/E | negative | |
| EV/Sales | 17.34 |
11 Analysts have issued a AbCellera Biologics Inc forecast for earnings per share. The average AbCellera Biologics Inc EPS is
This results in the following potential growth metrics and future valuations:
AbCellera Biologics Inc...
Current AbCellera Biologics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Keybanc |
Locked
➜
Locked
|
Locked | Jul 14 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | May 16 2025 |
| Keybanc |
Locked
➜
Locked
|
Locked | Apr 16 2025 |
| Benchmark |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Keybanc:
Locked
➜
Locked
|
Jul 14 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
Keybanc:
Locked
➜
Locked
|
Apr 16 2025 |
|
Locked
Benchmark:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Feb 28 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
